Contraceptive Technology Update – June 1, 2006
June 1, 2006
View Issues
-
Crystal methamphetamine use poses sexual health risks in women and men
Call it "crystal," "tina," or "crank," use of crystal methamphetamine is cutting across all socioeconomic and sexual boundaries. How does that affect your family planning facility? -
AIDS drugs may hold HIV prevention promise
Early research in rhesus monkeys indicates that a combination of two AIDS treatment drugs, tenofovir (TDF, Viread, Gilead; Foster City, CA) and emtricitabine (FTC, Emtriva; Gilead), may be effective in HIV prevention. -
At-risk teens? Help them to 'get teSTeD'
When it comes to sexually transmitted diseases (STDs), new data released by the American Social Health Association (ASHA) in Research Triangle Park, NC, shows that the average age of people who are tested for chlamydia is 28.9 for women and 30.5 for men. -
Where does your state stand on EC in the ED?
A new patient tells you that she is a recent victim of sexual assault. What care was she provided when she underwent treatment at your local hospital's emergency department (ED)? -
Mifepristone ruled out in one of two deaths
The Food and Drug Administration (FDA) has ruled out mifepristone (Mifeprex, Danco Laboratories, New York City) as the cause in one of two recent deaths of women who had taken the drug. The agency is continuing to investigate the other death. -
Check your approach to vaginal symptoms
Check the chart of your next patient. She says she has vaginal itching and irritation, odor, and vaginal discharge. What is your next step? -
CTU remembers Felicia Stewart, MD
Felicia Hance Stewart, MD, co-author of Contraceptive Technology and member of the Contraceptive Technology Update Editorial Board, died April 12 of lung cancer at her home in San Carlos, CA.